SCHEMBL93952

SCHEMBL93952

C#Cc1ccc(CC(N)C(=O)O)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SLC7A5 Q01650 3/20 0.62
▸ PTGS1 P23219 3/20 0.61
▸ ALPI P09923 1/20 0.61
▸ PKM P14618 1/20 0.61
▸ XIAP P98170 1/20 0.61
▸ PTPRC P08575 1/20 0.54
▸ HIF1A Q16665 5/20 0.53
▸ ALOX15 P16050 3/20 0.53
▸ KDM4E B2RXH2 2/20 0.53
▸ TDP1 Q9NUW8 2/20 0.53
▸ HSD17B10 Q99714 2/20 0.53
▸ USP2 O75604 1/20 0.53
▸ EGFR P00533 1/20 0.53
▸ LCK P06239 1/20 0.53
▸ FYN P06241 1/20 0.53
▸ ADORA3 P0DMS8 1/20 0.53
▸ HTR2A P28223 1/20 0.53
▸ PTGS2 P35354 1/20 0.53
▸ RECQL P46063 1/20 0.53
▸ TPH1 P17752 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL93953 1.00 SLC7A5 (0.62) SLC7A5PTGS1ALPIPKMXIAP
Hydrochloric Acid SCHEMBL31105583 0.98 SLC7A5 (0.61) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL2310526 0.84 SLC7A5 (0.83) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL43594 0.82 SLC7A5 (0.62) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL231561 0.82 SLC7A5 (0.62) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL838534 0.82 SLC7A5 (0.62) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL43593 0.82 SLC7A5 (0.62) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL231560 0.82 SLC7A5 (0.62) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL309210 0.81 SLC7A5 (0.70) SLC7A5PTGS1ALPIPKMXIAP
Hydrochloric Acid SCHEMBL1183792 0.81 SLC7A5 (0.61) SLC7A5PTGS1ALPIPKMXIAP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 588 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4659023-A1 METHOD OF PREDICTING SUCCESS OF A CANCER THERAPY Immusmol SAS (FR) 2025-12-10 — — EP claimed
US-12247320-B2 Multivalent glycopeptides that tightly bind to carbohydrate-binding monoclonal antibody family PGT128 BRANDEIS UNIVERSITY (US) 2025-03-11 — — US claimed
US-20250041439-A1 ANTIBODY-DRUG CONJUGATES SPIREA LIMITED (GB) 2025-02-06 — — US claimed
WO-2024161038-A1 METHOD OF PREDICTING SUCCESS OF A CANCER THERAPY IMMUSMOL SAS (FR) 2024-08-08 — — WO claimed
US-20230173092-A1 ANTIBODY-DRUG CONJUGATES SPIREA LIMITED (GB) 2023-06-08 — — US claimed
EP-4157357-A1 ANTIBODY-DRUG CONJUGATES Spirea Limited (GB) 2023-04-05 — — EP claimed
WO-2023047090-A1 ANTIBODY-DRUG CONJUGATES SPIREA LIMITED (GB) 2023-03-30 — — WO claimed
CN-115666653-A Antibody-drug conjugates 斯皮雷亚有限公司 2023-01-31 — — CN claimed
US-20230020297-A1 UOX-ALBUMIN CONJUGATE WITH CERTAIN NUMBERS OF ALBUMIN CONJUGATED THERETO, AND MANUFACTURING METHOD THEREOF PROABTECH CO., LTD. (KR) 2023-01-19 — — US claimed
WO-2021240155-A1 ANTIBODY-DRUG CONJUGATES SPIREA LIMITED (GB) 2021-12-02 — — WO claimed
WO-2008066583-A9 CELL-FREE SYNTHESIS OF PROTEINS CONTAINING UNNATURAL AMINO ACIDS UNIV LELAND STANFORD JUNIOR (US) 2008-07-24 — — WO claimed
WO-2008066583-A2 CELL-FREE SYNTHESIS OF PROTEINS CONTAINING UNNATURAL AMINO ACIDS THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2008-06-05 — — WO claimed
US-20080125347-A1 AMINO ACID SUBSTITUTED MOLECULES ALLOZYNE, INC. (US) 2008-05-29 — — US claimed
US-20080096819-A1 Amino acid substituted molecules ALLOZYNE, INC. (US) 2008-04-24 — — US claimed
US-20080044854-A1 SITE-SPECIFIC INCORPORATION OF AMINO ACIDS INTO MOLECULES CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2008-02-21 — — US claimed
WO-2007130453-A2 NON-NATURAL AMINO ACID SUBSTITUTED POLYPEPTIDES ALLOZYNE, INC. (US) 2007-11-15 — — WO claimed
WO-2007103307-A2 SITE-SPECIFIC INCORPORATION OF AMINO ACIDS INTO MOLECULES CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2007-09-13 — — WO claimed
WO-2007090198-A2 FLUORESCENT ASSAYS USING ORTHOGONAL TRNA - AMINOACYL SYNTHETASE PAIRS ENCODE BIO, INC. (US) 2007-08-09 — — WO claimed
US-7049336-B2 Immunosuppressants; antiallergens; modulation serotonin concentration MAX-DELBRUCK-CENTRUM FUR MOLEKULARC MEDIZIN (DE) 2006-05-23 — — US claimed
US-20040014656-A1 Method for diagnosing neuronal deseases and for treating primary hemostasis deficiency MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZIN (DE) 2004-01-22 — — US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080096819-A1 Amino acid substituted molecules BCAT2, DNPEP, PTMS SLC7A5 50/4885PTGS1 2652/4885ALPI 4832/4885
US-20230020297-A1 UOX-ALBUMIN CONJUGATE WITH CERTAIN NUMBERS OF ALBUMIN CONJUGATED THERETO, AND MANUFACTURING METHOD THEREOF DAO, ALB, DDO SLC7A5 343/4885PTGS1 1244/4885ALPI 1029/4885
US-20080044854-A1 SITE-SPECIFIC INCORPORATION OF AMINO ACIDS INTO MOLECULES AARS1, TRMT1, NSUN3 SLC7A5 110/4885PTGS1 3833/4885ALPI 4073/4885
US-12247320-B2 Multivalent glycopeptides that tightly bind to carbohydrate-binding monoclonal antibody family PGT128 CSGALNACT1, STT3A, GALNT14 SLC7A5 449/4885PTGS1 3699/4885ALPI 2546/4885
US-20230173092-A1 ANTIBODY-DRUG CONJUGATES CD44, CD47, FCGR3B SLC7A5 70/4885PTGS1 4517/4885ALPI 2840/4885
US-20250041439-A1 ANTIBODY-DRUG CONJUGATES CD44, CD47, FCGR3B SLC7A5 70/4885PTGS1 4517/4885ALPI 2840/4885
US-20080125347-A1 AMINO ACID SUBSTITUTED MOLECULES BCAT2, DNPEP, PTMS SLC7A5 50/4885PTGS1 2652/4885ALPI 4832/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback